Clinical trial
A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With…
NCT03197766 · BioMarin Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT03197766 |
|---|---|
| Title | A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia |
| Official title | A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia |
| Lead sponsor | BioMarin Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Achondroplasia |
| Intervention type | Drug |
| Interventions | BMN 111, Placebo |
| Enrollment | 121 |
| Start date | Dec 12, 2016 |
| Primary completion | Oct 30, 2019 |
| Completion | Oct 30, 2019 |
| First posted | Jun 23, 2017 |
| Last update posted | Mar 2, 2022 |
| Countries | Australia, Germany, Japan, Spain, Turkey (Türkiye), United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: